[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

Arcutis Biotherapeutics, Inc. Common Stock (ARQT)

ARQT stock surges to a 52-week high driven by strong Q3 earnings and anticipation of an FDA decision, despite a neutral rating from Goldman Sachs.

About Arcutis Biotherapeutics, Inc. Common Stock

Arcutis Biotherapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for dermatological conditions.
Arcutis Biotherapeutics, Inc. Common Stock uses the ticker $ARQT for trading. Listed in the Stocks category within the Healthcare sectors.

Insights

Arcutis Biotherapeutics, Inc. Common Stock (ARQT) social dominance hit XXXXX which is XXX% higher than it's daily average.
Arcutis Biotherapeutics, Inc. Common Stock (ARQT) market dominance near a 52-week low at XXXXXXX.
Arcutis Biotherapeutics, Inc. Common Stock (ARQT) trading volume is up XXXXXX% from the previous X months.
Arcutis Biotherapeutics, Inc. Common Stock (ARQT) social dominance is up 1066.67% from the previous X months.
Arcutis Biotherapeutics, Inc. Common Stock (ARQT) Galaxy Score™ is up XXXXX% from the previous month.

Price: $XX

Price 24-Hour Time-Series Raw Data
The stock price has surged to a 52-week high, supported by strong Q3 earnings, positive revenue growth, and anticipation of an FDA decision. High social media engagement and positive sentiment further bolster this upward trend.

24-Hour: -XXXX% 7-Day: -XXXX% 30-Day: XXXXX%

1-Year High: $XXXXX on 2025-12-05
1-Year Low: $XXXXX on 2025-02-11

AltRank: XXXXX

AltRank Line Chart
AltRank 24-Hour Time-Series Raw Data
Arcutis Biotherapeutics, Inc. Common Stock (ARQT) is currently AltRank #1,086 based on combined combined social and market metrics Daily Average: XXX
X Week: XXX +233
X Month: XXX -XX
1-Year High: XXXXX on 2025-11-07
1-Year Low: XXX on 2025-11-23

Galaxy Score: XXXXX

Galaxy Score Line Chart
Galaxy Score 24-Hour Time-Series Raw Data
Current Value: XXXXX
Daily Average: XX
X Week: XX +10
X Month: XX +12
1-Year High: XX on 2025-11-09
1-Year Low: XX on 2025-12-12

Engagements: XXXXX (24h)

Engagements Line Chart
Engagements 24-Hour Time-Series Raw Data
Current Value: XXXXX
Daily Average: XXXXXX
X Week: XXXXXX -XX%
X Month: XXXXXXX -XXXX%
X Months: XXXXXXXXX -XX%
X Year: XXXXXXXXX -XXXX%
1-Year High: XXXXXXX on 2025-02-21
1-Year Low: XXX on 2025-09-21

Engagements by network (24h): X: XXXXX

Mentions: XX (24h)

Mentions Line Chart
Mentions 24-Hour Time-Series Raw Data
Current Value: XX
Daily Average: XX
X Week: XXX -XX%
X Month: XXX +18%
X Months: XXXXX +70%
X Year: XXXXX -XX%
1-Year High: XXX on 2025-06-28
1-Year Low: XX on 2025-09-14

Mentions by network (24h): X: XXX

Creators: XX (24h)

Creators Line Chart
Creators 24-Hour Time-Series Raw Data
XX unique social accounts have posts mentioning Arcutis Biotherapeutics, Inc. Common Stock (ARQT) in the last XX hours which is up XX% from XX in the previous XX hours Daily Average: XX
X Week: XXX -XX%
X Month: XXX +5.30%
X Months: XXXXX +183%
X Year: XXXXX +146%
1-Year High: XXX on 2025-06-28
1-Year Low: X on 2025-09-21

The most influential creators that mention Arcutis Biotherapeutics, Inc. Common Stock in the last XX hours

Creator	Rank	Followers	Posts	Engagements
@equitydd	X	XXXXX	X	XXX
@RebellioMarket	X	XXXXXXX	X	XXX
@NightOwlBiotech	X	XXXXX	X	XXX
@SteveDJacobs	X	XXXXX	X	XXX
@Biotech2k1	X	XXXXXX	XX	XXX
@STvrosb	X	XXX	X	XXX
@BiopharmIQ	X	XXXXXX	X	XX
@BuyTheUgly	X	XX	X	XX
@gvanhp	X	XXX	X	XX
@seedytx19	XX	XXXXX	X	XX

Sentiment: XX%

Sentiment Line Chart
Sentiment 24-Hour Time-Series Raw Data
Current Value: XX%
Daily Average: XX%
X Week: XX% -XX%
X Month: XX% -XX%
X Months: XX% no change
X Year: XX% -XX%
1-Year High: XXX% on 2025-01-31
1-Year Low: XX% on 2025-09-23

Most Supportive Themes:

Positive Q3 Earnings and Revenue: (30%) Arcutis Biotherapeutics reported a profitable third quarter with revenue significantly exceeding expectations, driven by strong Zoryve sales.
FDA Decision Catalyst: (25%) An upcoming FDA decision for a topical foam treatment for psoriasis is viewed as a significant catalyst for the company.
Analyst Upgrades and Price Target Increases: (20%) Multiple analysts have raised their price targets for ARQT, with Goldman Sachs maintaining a Neutral rating and Mizuho raising their target significantly.

Most Critical Themes:

Neutral Analyst Rating: (15%) Despite positive Q3 results and revenue growth, Goldman Sachs maintains a 'Neutral' rating, suggesting a balanced outlook from this key analyst.

Social Dominance: XXXXX%

Social Dominance Line Chart
Social Dominance 24-Hour Time-Series Raw Data
Current Value: XXXXX%
Daily Average: XXXXX%
X Week: XXXX% +0.015%
X Month: XXXXX% +0.036%
X Months: XXXXX% +0.035%
X Year: XXXXX% +0.022%
1-Year High: XXXXX% on 2024-12-26
1-Year Low: XXXXXX% on 2025-09-14

Market Dominance: XXXXXXX%

Market Dominance Line Chart
Market Dominance 24-Hour Time-Series Raw Data
Current Value: XXXXXXX%
Daily Average: X%
1-Year High: XXXXX% on 2025-11-24
1-Year Low: XXXXXXX% on 2025-12-12

Market Cap: $XXXXXXXXXXXXX

Market Cap Line Chart
Market Cap 24-Hour Time-Series Raw Data
Current Value: $XXXXXXXXXXXXX
Daily Average: $XXXXXXXXXXXXX
X Week: $XXXXXXXXXXXXX -$6.30%
X Month: $XXXXXXXXXXXXX +$24%
1-Year High: $XXXXXXXXXXXXX on 2025-12-05
1-Year Low: $XXXXXXXXXXXXX on 2025-10-27

Top Arcutis Biotherapeutics, Inc. Common Stock Social Posts

Top posts by engagements in the last XX hours

Showing only X posts for non-authenticated requests. Use your API key in requests for full results.

"$IVVD $CERS $CRVS $ARQT TIME for the Christmas Rally"
X Link @STvrosb 2025-12-11T23:54Z XXX followers, XXX engagements

"Current top XX holdings. $HROW $CRVS (new) $KURA $NKTR $MDGL $MREO $NKTR $KALA $REGN $ABVX Sold $TARS $ARQT $NUVB"
X Link @FeldtInvesting 2025-12-10T15:51Z XXX followers, XXX engagements

"🚨 $ARQT : Trade Alert Breakout Potential 🚨 📈 Rating: 8.4/10 Potential: +94% A wide rounded daily cup with XX% depth and a clean rim at $XXXXX. The handle is compact and shallow formed above midline with controlled pullback and consistent volume contraction a structurally solid breakout from a long recovery base. 💎 Notes: Multiple resistance levels before the mid-path ATH increase the likelihood of a larger secondary cup forming during continuation. Opportunity Context: I missed the initial breakout price ran too quickly and then missed the pullback as well. I decided to seek an entry"
X Link @AdiPlaut 2025-12-10T12:32Z XXX followers, XX engagements

"New Highs : $AVGO $COLL $FIX $KRYS $LITE $TTMI $AUGO $BELFA $BELFB $CVNA $COHR $FIGS $FCAP $IESC $IRMD $FROG $NBIX $PWR $SND $PATH $VIAV $ARQT $ENVA $MTZ $MDB $RY $SMTC $BCAL $TRX $ALMS $FIVE $HTBK $MS $NUTX $ANAB $NTB $BK $EBC $ECPG $BE $JBL $NVT $NVT $PRIM $VRT $MSFT $FIVE:"
X Link @RebellioMarket 2025-12-10T04:49Z 150.9K followers, 3036 engagements